OptiNose (NASDAQ:OPTN - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.67, Zacks reports. The business had revenue of $21.47 million during the quarter, compared to the consensus estimate of $21.02 million.
OptiNose Stock Up 0.1 %
Shares of NASDAQ OPTN traded up $0.01 during trading hours on Monday, hitting $9.16. 69,867 shares of the stock were exchanged, compared to its average volume of 63,083. The company has a market cap of $92.10 million, a PE ratio of -2.18 and a beta of -0.30. OptiNose has a 12 month low of $4.82 and a 12 month high of $22.35. The firm has a fifty day moving average price of $6.30 and a 200-day moving average price of $7.90.
Insider Buying and Selling at OptiNose
In other news, CEO Ramy A. Mahmoud sold 6,376 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total transaction of $33,729.04. Following the completion of the sale, the chief executive officer now owns 126,931 shares in the company, valued at approximately $671,464.99. This represents a 4.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 8,213 shares of company stock worth $43,643 over the last three months. Corporate insiders own 2.30% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently commented on the stock. Piper Sandler reissued a "neutral" rating and issued a $9.00 price objective (down previously from $15.00) on shares of OptiNose in a research note on Friday, March 21st. Lake Street Capital downgraded OptiNose from a "buy" rating to a "hold" rating and cut their price target for the company from $17.00 to $9.00 in a report on Thursday, March 20th. Finally, HC Wainwright restated a "neutral" rating and set a $9.00 price objective (down from $18.00) on shares of OptiNose in a research note on Friday, March 21st.
Get Our Latest Report on OPTN
About OptiNose
(
Get Free Report)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
Featured Articles
Before you consider OptiNose, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptiNose wasn't on the list.
While OptiNose currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
